A Phase 2 interventional study of Selinexor in Glioblastoma and Glioma, sponsored by Karyopharm Therapeutics Inc. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 227th largest by enrollment of the 1,155 interventional ones that give a count, is one of 54 that started in 2014, is one of 396 in phase 2, and was the 599th registered.
2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Inova Health Care Services · Sites in United States
Ages 18–98
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 54 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 882 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 3 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
105 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 105 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
Initially, the study included 2 arms: an exploratory Surgical Arm (Arm A) with sequential enrollment for participants who require surgery and a medical arm (Arm B) for participants who are not eligible for surgery.
Enrollment in Arm B was stopped to explore alternative dosing in Protocol Versions ≥ 4.0 to potentially improve tolerability. Four arms (Arms C, D, E, and F) were added to the Medical Arm in Protocol Version 4.0. Arms E and F were eliminated in protocol version 6.0 and no participants were ever enrolled in these arms.
Participants in the primary population enrolled under Protocol Version ≥ 4.0 will be randomized to Arm C and Arm D (approximately 30 participants per arm) to explore alternative dosing to potentially improve tolerability.
After screening and registration/randomization in the study, participants enrolling in Arm A or randomized to Arm C will receive 60 mg selinexor orally twice weekly. Participants randomized to Arm D will receive 80 mg selinexor orally weekly.
Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo the End of Treatment (EOT) visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.
Drug: Selinexor
Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m\^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
Drug: Selinexor
Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
Drug: Selinexor
Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
Drug: Selinexor
One cycle is 28 days (4 weeks).
Also known as: KPT-330
6-Month Progression-Free Survival (PFS) Rate
The analysis of 6mPFS was performed by calculating the estimated survival probability of having PFS ≥ 6 months based on Kaplan-Meier method, where PFS was defined as the time from the start of study treatment until first documented progression based on Response Assessment in Neuro-Oncology (RANO) criteria, or death from any cause. Progressive disease occurs when either of the criteria was present: greater than or equal to (≥) 25 percentage (%) increase in T1 gadolinium enhancing disease, increase in T2/ Fluid-attenuated inversion recovery (FLAIR), detection of new lesions, or decreased clinical status.
Time frame: From start of study treatment up to disease progression or death, whichever occurred first (assessed up to Month 6)
Overall Response Rate (ORR)
The ORR was determined as percentage of participants who had either complete response (CR) or partial response (PR) using the RANO criteria. CR: No T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, no corticosteroid use and stable, or increasing clinical status. PR: ≥50% decrease in T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, stable or decreased use of corticosteroids, and stable or increased clinical status.
Time frame: Up to 71 months
Overall Survival (OS)
The OS was calculated from the date of start of study treatment to the date of death. Participants who were still alive prior to the data cut-off for final efficacy analysis, or who dropout prior to study end, were censored on the day they were last known to be alive. The OS was estimated using Kaplan-Meier method.
Time frame: From date of study treatment up to date of death (assessed up to 71 months)
Progression-free Survival (PFS)
The PFS was calculated from the date of start of study treatment to the date of disease progression based on RANO criteria, or date of death should progression not have occurred. Progressive disease occurs when either of the criteria was present: ≥25% increase in T1 gadolinium enhancing disease, increased T2/FLAIR, detection of new lesions, or decreased clinical status.
Time frame: From start of study treatment up to disease progression (assessed up to 71 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was defined as an AE that was fatal; life threatening (places the participant at immediate risk of death); requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; and other important medical events. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the Investigator through the end of the study. TEAEs included both serious and non-serious TEAEs.
Time frame: From start of study treatment administration up to 71 months
This study was conducted at 6 sites across the United States of America, Denmark and Netherland between 03 March 2014 and 23 January 2020.
| Milestone | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|---|
| Started | 8 | 24 | 14 | 30 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 8 | 24 | 14 | 30 |
| Withdrew: Death | 8 | 22 | 10 | 21 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by participant | 0 | 1 | 2 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 3 |
| Withdrew: Other-unspecified | 0 | 1 | 0 | 2 |
The analysis of 6mPFS was performed by calculating the estimated survival probability of having PFS ≥ 6 months based on Kaplan-Meier method, where PFS was defined as the time from the start of study treatment until first documented progression based on Response Assessment in Neuro-Oncology (RANO) criteria, or death from any cause. Progressive disease occurs when either of the criteria was present: greater than or equal to (≥) 25 percentage (%) increase in T1 gadolinium enhancing disease, increase in T2/ Fluid-attenuated inversion recovery (FLAIR), detection of new lesions, or decreased clinical status.
| percentage of participants | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|
| 6-Month Progression-Free Survival (PFS) Rate | 9.72 (2.67 to 35.39) | 7.69 (1.17 to 50.57) | 17.24 (7.77 to 38.27) |
The ORR was determined as percentage of participants who had either complete response (CR) or partial response (PR) using the RANO criteria. CR: No T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, no corticosteroid use and stable, or increasing clinical status. PR: ≥50% decrease in T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, stable or decreased use of corticosteroids, and stable or increased clinical status.
| percentage of participants | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|
| Overall Response Rate (ORR) | 8.3 (1.0 to 27.0) | 7.7 (0.2 to 36.0) | 10.0 (2.1 to 26.5) |
The OS was calculated from the date of start of study treatment to the date of death. Participants who were still alive prior to the data cut-off for final efficacy analysis, or who dropout prior to study end, were censored on the day they were last known to be alive. The OS was estimated using Kaplan-Meier method.
| months | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|
| Overall Survival (OS) | 10.51 (4.93 to 16.95) | 8.48 (7.29 to NA) | 10.15 (7.03 to 15.38) |
The PFS was calculated from the date of start of study treatment to the date of disease progression based on RANO criteria, or date of death should progression not have occurred. Progressive disease occurs when either of the criteria was present: ≥25% increase in T1 gadolinium enhancing disease, increased T2/FLAIR, detection of new lesions, or decreased clinical status.
| months | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|
| Progression-free Survival (PFS) | 1.64 (1.18 to 3.15) | 1.87 (1.84 to 14.88) | 1.87 (1.81 to 3.02) |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was defined as an AE that was fatal; life threatening (places the participant at immediate risk of death); requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; and other important medical events. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the Investigator through the end of the study. TEAEs included both serious and non-serious TEAEs.
| Participants | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|---|
| Participants with TEAEs | 8 | 24 | 14 | 30 |
| Participants with TESAEs | 5 | 7 | 7 | 7 |
Collected over From start of study treatment administration up to 71 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Selinexor 60 mg and Surgery | 8/8 (100%) | 5/8 (62.5%) | 8/8 (100%) |
| Arm B: Selinexor 50 mg/m^2 | 22/24 (91.7%) | 7/24 (29.2%) | 24/24 (100%) |
| Arm C: Selinexor 60 mg | 10/14 (71.4%) | 7/14 (50%) | 14/14 (100%) |
| Arm D: Selinexor 80 mg | 21/30 (70%) | 7/30 (23.3%) | 30/30 (100%) |
| Event | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|---|
| SeizureNervous system disorders | 0/8 | 1/24 | 3/14 | 2/30 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| Meningitis bacterialInfections and infestations | 1/8 | 0/24 | 0/14 | 0/30 |
| Staphylococcal infectionInfections and infestations | 1/8 | 0/24 | 0/14 | 0/30 |
| Decreased appetiteMetabolism and nutrition disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| Cerebrospinal fluid leakageNervous system disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| Cerebrovascular accidentNervous system disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| PneumocephalusNervous system disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| Confusional statePsychiatric disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| EmbolismVascular disorders | 1/8 | 0/24 | 0/14 | 0/30 |
| Event | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg |
|---|---|---|---|---|
| FatigueGeneral disorders | 5/8 | 19/24 | 11/14 | 16/30 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/8 | 16/24 | 6/14 | 11/30 |
| NauseaGastrointestinal disorders | 6/8 | 12/24 | 9/14 | 21/30 |
| Decreased appetiteMetabolism and nutrition disorders | 3/8 | 12/24 | 10/14 | 8/30 |
| Gait disturbanceGeneral disorders | 5/8 | 5/24 | 3/14 | 3/30 |
| ConstipationGastrointestinal disorders | 3/8 | 8/24 | 7/14 | 7/30 |
| HyponatraemiaMetabolism and nutrition disorders | 4/8 | 11/24 | 3/14 | 1/30 |
| HeadacheNervous system disorders | 4/8 | 5/24 | 6/14 | 5/30 |
| LeukopeniaBlood and lymphatic system disorders | 0/8 | 7/24 | 1/14 | 14/30 |
| VomitingGastrointestinal disorders | 1/8 | 9/24 | 5/14 | 13/30 |
Safety population consisted of all participants who had received any amount of study treatment.
| Age, Continuous(Years) | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg | Total |
|---|---|---|---|---|---|
| Mean | 56.6 ± 6.70 | 51.1 ± 13.04 | 49.5 ± 12.36 | 54.3 ± 11.98 | 52.7 ± 11.99 |
| Sex: Female, Male(Participants) | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg | Total |
|---|---|---|---|---|---|
| Female | 1 | 5 | 5 | 11 | 22 |
| Male | 7 | 19 | 9 | 19 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 3 | 3 |
| Not Hispanic or Latino | 8 | 20 | 8 | 24 | 60 |
| Unknown or Not Reported | 0 | 4 | 6 | 3 | 13 |
| Race (NIH/OMB)(Participants) | Arm A: Selinexor 60 mg and Surgery | Arm B: Selinexor 50 mg/m^2 | Arm C: Selinexor 60 mg | Arm D: Selinexor 80 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 8 | 24 | 8 | 25 | 65 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 6 | 4 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2014 to primary completion in Jan 2020, 70 months.
Results were first posted in Aug 2021, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor